Welcome!

News Feed Item

Stammering Global Clinical Trials Review, H2, 2014

NEW YORK, Aug. 11, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Stammering Global Clinical Trials Review, H2, 2014

http://www.reportlinker.com/p02280948/Stammering-Global-Clinical-Trials-Review-H2-2014.html

Stammering Global Clinical Trials Review, H2, 2014

Summary

GlobalData's clinical trial report, "Stammering Global Clinical Trials Review, H2, 2014" provides data on the Stammering clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Stammering. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Stammering. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Introduction 5
Stammering 5
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Countries Contributing to Clinical Trials in Asia-Pacific 9
Top Countries Contributing to Clinical Trials in Europe 10
Top Countries Contributing to Clinical Trials in North America 11
Top Countries Contributing to Clinical Trials in Central and South America 12
Clinical Trials by G7 Countries: Proportion of Stammering to Central Nervous System Clinical Trials 13
Clinical Trials by Phase in G7 Countries 14
Clinical Trials in G7 Countries by Trial Status 15
Clinical Trials by E7 Countries: Proportion of Stammering to Central Nervous System Clinical Trials 16
Clinical Trials by Phase 17
In Progress Trials by Phase 18
Clinical Trials by Trial Status 19
Clinical Trials by End Point Status 20
Unaccomplished Trials of Stammering 21
Subjects Recruited Over a Period of Time 22
Clinical Trials by Sponsor Type 23
Prominent Sponsors 24
Clinical Trial Profiles 25
Clinical Trial Overview of Top Companies 25
Endo International plc 25
Clinical Trial Overview of Endo International plc 25
Clinical Trial Overview of Top Institutes / Government 26
National Institute on Deafness and Other Communication Disorders 26
Clinical Trial Overview of National Institute on Deafness and Other Communication Disorders 26
National Institute of Neurological Disorders and Stroke 27
Clinical Trial Overview of National Institute of Neurological Disorders and Stroke 27
The University of Sydney 28
Clinical Trial Overview of The University of Sydney 28
Tbilisi State Medical University 29
Clinical Trial Overview of Tbilisi State Medical University 29
Universidade Federal de Minas Gerais 30
Clinical Trial Overview of Universidade Federal de Minas Gerais 30
Pharmacology Research Institute 31
Clinical Trial Overview of Pharmacology Research Institute 31
The Newcastle upon Tyne Hospitals NHS Foundation Trust 32
Clinical Trial Overview of The Newcastle upon Tyne Hospitals NHS Foundation Trust 32
Universitatsklinikum Munster 33
Clinical Trial Overview of Universitatsklinikum Munster 33
University of California, Irvine 34
Clinical Trial Overview of University of California, Irvine 34
Five Key Clinical Profiles 35
Appendix 50
Abbreviations 50
Definitions 50
Research Methodology 51
Secondary Research 51
About GlobalData 52
Contact Us 52
Disclaimer 52
Source 52

List of Tables

Stammering Therapeutics, Global, Clinical Trials by Region, 2014* 6
Stammering Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 7
Stammering Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 8
Stammering Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2014* 9
Stammering Therapeutics Clinical Trials, Europe, Top Countries, 2014* 10
Stammering Therapeutics Clinical Trials, North America, Top Countries, 2014* 11
Stammering Therapeutics Clinical Trials, Central and South America, Top Countries, 2014* 12
Proportion of Stammering to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 13
Stammering Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 14
Stammering Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 15
Proportion of Stammering to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 16
Stammering Therapeutics, Global, Clinical Trials by Phase, 2014* 17
Stammering Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 18
Stammering Therapeutics, Global, Clinical Trials by Trial Status, 2014* 19
Stammering Therapeutics Clinical Trials, Global, by End Point Status, 2014* 20
Stammering Therapeutics, Global, Suspended Clinical Trials, 2014* 21
Stammering Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 22
Stammering Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 23
Stammering Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 24
Stammering Therapeutics Clinical Trials Market, Global, Clinical Trials by Endo International plc, 2014* 25
Stammering Therapeutics Clinical Trials Market, Global, Clinical Trials by National Institute on Deafness and Other Communication Disorders, 2014* 26
Stammering Therapeutics Clinical Trials Market, Global, Clinical Trials by National Institute of Neurological Disorders and Stroke, 2014* 27
Stammering Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Sydney, 2014* 28
Stammering Therapeutics Clinical Trials Market, Global, Clinical Trials by Tbilisi State Medical University, 2014* 29
Stammering Therapeutics Clinical Trials Market, Global, Clinical Trials by Universidade Federal de Minas Gerais, 2014* 30
Stammering Therapeutics Clinical Trials Market, Global, Clinical Trials by Pharmacology Research Institute, 2014* 31
Stammering Therapeutics Clinical Trials Market, Global, Clinical Trials by The Newcastle upon Tyne Hospitals NHS Foundation Trust, 2014* 32
Stammering Therapeutics Clinical Trials Market, Global, Clinical Trials by Universitatsklinikum Munster, 2014* 33
Stammering Therapeutics Clinical Trials Market, Global, Clinical Trials by University of California, Irvine, 2014* 34

List of Figures

Stammering Therapeutics, Global, Clinical Trials by Region (%), 2014* 6
Stammering Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 7
Stammering Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 8
Stammering Therapeutics Clinical Trials, Europe, Top Countries (%), 2014* 10
Stammering Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 11
Proportion of Stammering to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 13
Stammering Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 14
Stammering Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 15
Proportion of Stammering to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 16
Stammering Therapeutics, Global, Clinical Trials by Phase (%), 2014* 17
Stammering Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 18
Stammering Therapeutics, Global, Clinical Trials by Trial Status, 2014* 19
Stammering Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 22
Stammering Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 23
GlobalData Methodology 51

To order this report: Stammering Global Clinical Trials Review, H2, 2014
http://www.reportlinker.com/p02280948/Stammering-Global-Clinical-Trials-Review-H2-2014.html

_________________________
Contact Clare: [email protected]
US:(339) 368 6001
Intl:+1 339 368 6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
The technologies behind big data and cloud computing are converging quickly, offering businesses new capabilities for fast, easy, wide-ranging access to data. However, to capitalize on the cost-efficiencies and time-to-value opportunities of analytics in the cloud, big data and cloud technologies must be integrated and managed properly. Pythian's Director of Big Data and Data Science, Danil Zburivsky will explore: The main technology components and best practices being deployed to take advantage...
Andi Mann, Chief Technology Advocate at Splunk, is an accomplished digital business executive with extensive global expertise as a strategist, technologist, innovator, marketer, and communicator. For over 30 years across five continents, he has built success with Fortune 500 corporations, vendors, governments, and as a leading research analyst and consultant.
Cloud-enabled transformation has evolved from cost saving measure to business innovation strategy -- one that combines the cloud with cognitive capabilities to drive market disruption. Learn how you can achieve the insight and agility you need to gain a competitive advantage. Industry-acclaimed CTO and cloud expert, Shankar Kalyana presents. Only the most exceptional IBMers are appointed with the rare distinction of IBM Fellow, the highest technical honor in the company. Shankar has also receive...
Most DevOps journeys involve several phases of maturity. Research shows that the inflection point where organizations begin to see maximum value is when they implement tight integration deploying their code to their infrastructure. Success at this level is the last barrier to at-will deployment. Storage, for instance, is more capable than where we read and write data. In his session at @DevOpsSummit at 20th Cloud Expo, Josh Atwell, a Developer Advocate for NetApp, will discuss the role and value...
Today, we have more data to manage than ever. We also have better algorithms that help us access our data faster. Cloud is the driving force behind many of the data warehouse advancements we have enjoyed in recent years. But what are the best practices for storing data in the cloud for machine learning and data science applications?
DXWorldEXPO LLC announced today that ICOHOLDER named "Media Sponsor" of Miami Blockchain Event by FinTechEXPO. ICOHOLDER gives detailed information and help the community to invest in the trusty projects. Miami Blockchain Event by FinTechEXPO has opened its Call for Papers. The two-day event will present 20 top Blockchain experts. All speaking inquiries which covers the following information can be submitted by email to [email protected] Miami Blockchain Event by FinTechEXPOalso offers sp...
DXWordEXPO New York 2018, colocated with CloudEXPO New York 2018 will be held November 11-13, 2018, in New York City and will bring together Cloud Computing, FinTech and Blockchain, Digital Transformation, Big Data, Internet of Things, DevOps, AI, Machine Learning and WebRTC to one location.
Bill Schmarzo, author of "Big Data: Understanding How Data Powers Big Business" and "Big Data MBA: Driving Business Strategies with Data Science" is responsible for guiding the technology strategy within Hitachi Vantara for IoT and Analytics. Bill brings a balanced business-technology approach that focuses on business outcomes to drive data, analytics and technology decisions that underpin an organization's digital transformation strategy.
DevOpsSummit New York 2018, colocated with CloudEXPO | DXWorldEXPO New York 2018 will be held November 11-13, 2018, in New York City. Digital Transformation (DX) is a major focus with the introduction of DXWorldEXPO within the program. Successful transformation requires a laser focus on being data-driven and on using all the tools available that enable transformation if they plan to survive over the long term.
@DevOpsSummit at Cloud Expo, taking place November 12-13 in New York City, NY, is co-located with 22nd international CloudEXPO | first international DXWorldEXPO and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The widespread success of cloud computing is driving the DevOps revolution in enterprise IT. Now as never before, development teams must communicate and collaborate in a dynamic, 24/7/365 environment. There is no time t...
Headquartered in Plainsboro, NJ, Synametrics Technologies has provided IT professionals and computer systems developers since 1997. Based on the success of their initial product offerings (WinSQL and DeltaCopy), the company continues to create and hone innovative products that help its customers get more from their computer applications, databases and infrastructure. To date, over one million users around the world have chosen Synametrics solutions to help power their accelerated business or per...
DXWorldEXPO LLC announced today that Kevin Jackson joined the faculty of CloudEXPO's "10-Year Anniversary Event" which will take place on November 11-13, 2018 in New York City. Kevin L. Jackson is a globally recognized cloud computing expert and Founder/Author of the award winning "Cloud Musings" blog. Mr. Jackson has also been recognized as a "Top 100 Cybersecurity Influencer and Brand" by Onalytica (2015), a Huffington Post "Top 100 Cloud Computing Experts on Twitter" (2013) and a "Top 50 C...
Charles Araujo is an industry analyst, internationally recognized authority on the Digital Enterprise and author of The Quantum Age of IT: Why Everything You Know About IT is About to Change. As Principal Analyst with Intellyx, he writes, speaks and advises organizations on how to navigate through this time of disruption. He is also the founder of The Institute for Digital Transformation and a sought after keynote speaker. He has been a regular contributor to both InformationWeek and CIO Insight...
When talking IoT we often focus on the devices, the sensors, the hardware itself. The new smart appliances, the new smart or self-driving cars (which are amalgamations of many ‘things'). When we are looking at the world of IoT, we should take a step back, look at the big picture. What value are these devices providing. IoT is not about the devices, its about the data consumed and generated. The devices are tools, mechanisms, conduits. This paper discusses the considerations when dealing with the...
They say multi-cloud is coming, but organizations are leveraging multiple clouds already. According to a study by 451 Research, only 21% of organizations were using a single cloud. If you've found yourself unprepared for the barrage of cloud services introduced in your organization, you will need to change your approach to engaging with the business and engaging with vendors. Look at technologies that are on the way and work with the internal players involved to have a plan in place when the ine...